Background
Transcatheter aortic valve implantation (TAVI) is an alternative for surgery in patients at high surgical risk. We would like to describe our single-center multimodality experience with transfemoral, transaxillary and transapical TAVI procedures using CoreValve and Edwards-Sapien devices.
Methods
By November 2010, 67 patients were treated: 32 transfemoral Corevalve, 7 transaxillary CoreValve, 14 transfemoral Edwards and 14 transapical Edwards. This patient group (65% women) was characterized by relatively older age (mean 82.8±4.8 years) and high prevalence of severe comorbidities: 33% diabetes mellitus, 40% postthoracotomy, 44% chronic renal failure, 24% chronic pulmonary disease. The mean calculated logistic euroSCORE was 21.5%±15% and STS score was 8.1%±5.4%. Four TAVI cases (6%) were performed in bioprosthetic valves.
Methods
By November 2010, 67 patients were treated: 32 transfemoral Corevalve, 7 transaxillary CoreValve, 14 transfemoral Edwards and 14 transapical Edwards. This patient group (65% women) was characterized by relatively older age (mean 82.8±4.8 years) and high prevalence of severe comorbidities: 33% diabetes mellitus, 40% postthoracotomy, 44% chronic renal failure, 24% chronic pulmonary disease. The mean calculated logistic euroSCORE was 21.5%±15% and STS score was 8.1%±5.4%. Four TAVI cases (6%) were performed in bioprosthetic valves.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
